In people with type 1 diabetes using multiple daily injections of insulin plus isCGM and with HbA1c of at least 8%, the use of AHCL confers benefits in terms of glycaemic control beyond those that can be achieved with multiple daily injections of insulin plus isCGM. These data support wider access to AHCL in people with type 1 diabetes not at target glucose levels (The Lancet Diabetes & Endocrinology)
Diabetes News
Tag: Type 1 Diabetes
Open-source Closed-Loop System Is Effective for Type 1 Diabetes
The study adds to a growing body of evidence that AID systems, including commercial AIDs, are “remarkably consistent” in keeping blood glucose in target range, according to an editorial that accompanied the findings in the New England Journal of Medicine (JAMA)
Intermittently Scanned Continuous Glucose Monitoring for Type 1 Diabetes
Among participants with type 1 diabetes and high glycated hemoglobin levels, the use of intermittently scanned continuous glucose monitoring with optional alarms for high and low blood glucose levels resulted in significantly lower glycated hemoglobin levels than levels monitored by fingerstick testing (NEJM)
Factors associated with favourable 5 year outcomes in islet transplant alone recipients with type 1 diabetes complicated by severe hypoglycaemia in the Collaborative Islet Transplant Registry
In recipients with type 1 diabetes complicated by SHEs, islet transplantation meeting 4CFF protected 95% from SHEs at 5 years after the last islet infusion and exerted a large and significant benefit on glycaemic control, with an acceptable safety profile for this subgroup of type 1 diabetes (Diabetologia)
The Insulin-Only Bionic Pancreas Pivotal Trial Extension Study
A Multi-Center Single-Arm Evaluation of the Insulin-Only Configuration of the Bionic Pancreas in Adults and Youth with Type 1 Diabetes (Diabetes Technology and Therapeutics)
Real-world glycaemic outcomes in adult persons with type 1 diabetes using a real-time continuous glucose monitor compared to an intermittently scanned glucose monitor
A retrospective observational study from the Canadian LMC diabetes registry (REAL-CGM-T1D) (Diabetic Medicine)
Open-Source Automated Insulin Delivery in Type 1 Diabetes
In children and adults with type 1 diabetes, the use of an open-source AID system resulted in a significantly higher percentage of time in the target glucose range than the use of a sensor-augmented insulin pump at 24 weeks (NEJM)
Closed-Loop Therapy and Preservation of C-Peptide Secretion in Type 1 Diabetes
In youths with new-onset type 1 diabetes, intensive glucose control for 24 months did not appear to prevent the decline in residual C-peptide secretion (NEJM)
Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study
In people with type 1 diabetes using multiple daily injections of insulin plus isCGM and with HbA1c of at least 8%, the use of AHCL confers benefits in terms of glycaemic control beyond those that can be achieved with multiple daily injections of insulin plus isCGM. These data support wider access to AHCL in people with type 1 diabetes not at target glucose levels (The Lancet Diabetes & Endocrinology)
The Gut Microbiome Composition Is Altered in Long-standing Type 1 Diabetes and Associates With Glycemic Control and Disease-Related Complications
Our data show that the gut microbiome is altered in people with (long-standing) type 1 diabetes and is associated with glycemic control and diabetes-related complications. As a result of the cross-sectional design, the causality of these relationships remains to be determined (Diabetes Care)
Impact of glycaemic technologies on quality of life and related outcomes in adults with type 1 diabetes: a narrative review
PROs are usually assessed as secondary outcomes in glycaemic technology studies. Hypoglycaemia-specific and diabetes-specific, but not generic, PROs show benefits of glycaemic technologies, and deserve a more central role in future studies as well as routine clinical care (Diabetic Medicine)
Precision medicine in type 1 diabetes
In this review, we discuss how these personalised approaches have improved diabetes care and how improved understanding of pathogenesis and human biology might inform precision medicine in the future (Diabetologia)
Live enteroviruses, but not other viruses, detected in human pancreas at the onset of type 1 diabetes in the DiViD study
Sensitive assays confirm that the pancreases of all DiViD cases contain EVs but no other viruses (Diabetologia)
NHS To roll out life-changing glucose monitors to all Type 1 diabetes patients
NHS England patients with Type 1 diabetes will now be eligible for life-changing continuous glucose monitors after the health service secured a new cut-price deal (NHS England)
Two-age islet-autoantibody screening for childhood type 1 diabetes: a prospective cohort study
Our results show that initial screening for islet autoantibodies at two ages (2 years and 6 years) is sensitive and efficient for public health translation but might require adjustment by country on the basis of population-specific disease characteristics (The Lancet Diabetes & Endocrinology)
Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association
The scope of this American Diabetes Association (ADA) consensus report with designated representation from the American College of Cardiology (ACC) is to provide clear guidance and to recommend best approaches to general internists, primary care providers, and endocrinologists for HF screening, diagnosis, and management in individuals with T1D, T2D, or prediabetes (Diabetes Care)
Association Between the Tissue and Circulating Advanced Glycation End-Products and the Micro- and Macrovascular Complications in Type 1 Diabetes: The DIABAGE Study
Skin autofluorescence appears to be a useful marker for investigating both micro- and macrovascular complications in T1D. In this study, pentosidine was associated with macroangiopathy and MGH1 with nephropathy among the circulating AGEs. Furthermore, the correlations between PWV and AGEs may suggest their value in early prediction of vascular complications in T1D (Diabetes Therapy )
Type 1 diabetes in adults: diagnosis and management
This guideline covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It includes advice on diagnosis, education and support, blood glucose management, cardiovascular risk, and identifying and managing long-term complications (NICE)
Diabetes (type 1 and type 2) in children and young people: diagnosis and management
This guideline covers the diagnosis and management of type 1 and type 2 diabetes in children and young people aged under 18. The guideline recommends how to support children and young people and their families and carers to maintain tight control of blood glucose to reduce the long-term risks associated with diabetes (NICE)
Risky self-management behaviors in adolescents with type 1 diabetes: Measurement validation for the Diabetes-Specific Risk-Taking Inventory (DSRI)
Overall, initial psychometrics suggest the DSRI is a reliable and valid measure of risks that adolescents may take with their T1D care. This innovative self-report measure has potential to be an actionable clinical tool to screen for high-risk behaviors not routinely assessed in T1D clinical care (Pediatric Diabetes)
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 24
- Next Page »
Glycosmedia is also available as an App: